Agreements and pacts - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Agreements and pacts
The latest pacts from the pharmaceutical supply chain

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 3, Issue 9

Mumbai (Aug. 6)Novartis (Basel, Switzerland) reported that the High Court in Chennai dismissed its writ petition challenging the constitutionality of Section 3(d), and deferred to the World Trade Organization (WTO) forum to resolve the TRIPS compliance question. India denied Novartis's patent application for the anticancer drug "Gleevec/Glivec" (imatinib) in 2006.

"We disagree with this ruling, however we likely will not appeal to the Supreme Court. We await the full decision to better understand the Court's position," said Ranjit Shahani, vice-chairman and managing director with Novartis India Limited, in a company release. "Our actions advanced this essential debate in India; now local and international leaders in both industry and academia recognize the inadequacies of Section 3(d) and are raising serious concerns about the deficiencies of the Indian patent system."

Novartis originally filed the appeal in India because the Indian patent office rejected the Gleevec/Glivec patent application. "Because the patent rejection was based on Section 3(d), we challenged this specific provision in India," said Shahani. "We had hoped to resolve this question on Section 3(d) locally in order to receive a patent for Glivec."

Novartis says still at issue is why a patent for Glivec was denied in India in 2006. The Glivec patent appeal will be decided separately by the newly-operational Intellectual Property Appellate Board (IPAB). Novartis also is petitioning the High Court for a new technical member because the current technical member is the former Controller General of the Indian Patent Office, responsible for the original rejection of the Glivec patent.

"We expect the appellate board to conduct an independent and impartial review of our appeal and ensure transparency of the decision-making process," said Shahani in a company release.

London (Aug. 2)AstraZeneca selected Kuehne + Nagel (Jersey City, NJ) to handle part of its exports of temperature-sensitive pharmaceutical products from Europe to the rest of the world. Under the agreement, Kuehne + Nagel will supply a complete solution for the transportation by air and sea of products indicated for therapeutic categories, including oncology and anesthetics, as well as active pharmaceutical ingredients.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
25%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
36%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here